Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06444815 · ClinicalTrials.gov registry record · Phase 1
A Study of VET3-TGI in Patients With Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Cervical Cancer, sponsored by KaliVir Immunotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT06444815: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Cervical Cancer, sponsored by KaliVir Immunotherapeutics.
NCT06444815 is a Phase 1 study of Non-Small Cell Lung Cancer and Cervical Cancer that is actively recruiting participants, run by KaliVir Immunotherapeutics. The registered enrollment target is 60 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06444815, a Phase 1 study of Non-Small Cell Lung Cancer and Cervical Cancer, is actively recruiting participants, sponsored by KaliVir Immunotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
Primary Outcome
Percentage of patients with adverse events by grade as determined by NCI CTCAE v5.0
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG VET3-TGI
Study Locations (7)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- UC Irvine Health - Orange
Texas
- Mary Crowley Cancer Research - Dallas
- University of Texas MD Anderson Cancer Center - Houston
Florida
- University of Miami - Miami
Indiana
- Community Health Network - Indianapolis
Pennsylvania
- UPMC- Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT06444815 shows while recruiting
NCT06444815 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower).
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06444815 lists 7 locations in 5 states (California, Texas, Florida).
Frequently Asked Questions
What is clinical trial NCT06444815 about?
NCT06444815 is a clinical study titled "A Study of VET3-TGI in Patients With Solid Tumors". VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when...
What is the current status of trial NCT06444815?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-09-16. Estimated completion is 2027-12-31.
What conditions does trial NCT06444815 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Solid Tumor, Adult.
What interventions are being tested in trial NCT06444815?
The interventions under investigation include: Pembrolizumab (DRUG), VET3-TGI (DRUG).
Who is sponsoring clinical trial NCT06444815?
This trial is sponsored by KaliVir Immunotherapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06444815 being conducted?
This trial has 7 study locations across California, Florida, Indiana, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06444815's enrollment target sits among peer trials
60 313th of 454 higher than 135 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI